• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors

    8/26/21 6:45:00 AM ET
    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRR alert in real time by email

    CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde's arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2 in an advisory capacity.

    "As we continue to advance gavo-cel in clinical trials across multiple cancer indications and simultaneously innovate our TRuC-T cells in ways to persist longer in the hostile solid tumor microenvironment, Dr. Hegde will play a pivotal role in helping us understand how our cancer patients are responding to TRuC-T cells," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "Her extensive experience in cancer immunology and in particular her expertise in translational medicine and companion diagnostics will guide us in our pursuit to design better clinical assays, enabling us to determine which combinations or enhancements will allow our TRuC-T cells to provide maximum benefit to patients in difficult-to-treat indications. Once again, we are thrilled be adding to the board such a highly regarded scientist with expertise specific to the needs of the company."

    Dr. Hegde currently serves as Chief Scientific Officer at Foundation Medicine, Inc., where she oversees clinical product development, cancer genomics, regulatory and early stage research to advance their leading comprehensive genomic profiling portfolio. Previously, Dr. Hegde held roles of increasing responsibility at Genentech for 12 years, where she served as senior director and principal scientist in oncology biomarker development, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy and was responsible for clinical translation strategies for more than 18 therapeutic programs in over 100 Phase I-III global clinical trials. Dr. Hegde was also instrumental in the approvals for Tecentriq® (atezolizumab), a PD-L1 immunotherapy, in both the United States and European Union, as well as its forthcoming diagnostic filings. Prior to joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline. She completed her post-doctoral fellowship at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy degree from Mumbai University, India.

    "To work with a company developing a truly unique cell therapy modality which can overcome the limitations of both CAR- and TCR-T therapies in solid tumors represents a great base to innovate a path forward using translational medicine," said Dr. Hegde. "I am delighted to join the TCR2 board at a time when the company is rapidly expanding beyond gavo-cel with a rich pipeline of new targets and enhancements to TRuC-T cells which could benefit a significant number of cancer patients."

    "On behalf of the company and the entire TCR2 board, I also want to recognize Patrick Baeuerle for his many contributions and commitment to the company's vision and scientific excellence. The TRuC-T cell, his truly original idea, is now a clinical product providing benefit to cancer patients with solid tumors and his ongoing innovation has enabled us to create next generation approaches in our expanding pipeline," commented Dr. Menzel. "We literally would not exist without Dr. Baeuerle and we are grateful that we will continue to benefit from his insights as he transitions from a Board member to a consultant."

    About TCR2 Therapeutics

    TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokines. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.

    Forward-looking Statements

    This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of gavo-cel, timing for interim updates for the gavo-cel and TC-110 clinical trials, expectations regarding manufacturing plans and capabilities, future clinical development and commercialization plans, the development of the Company's TRuC-T cells, their potential characteristics, applications and clinical utility, and the potential therapeutic applications of the Company's TRuC-T cell platform.

    The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2's ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2's ability to secure additional manufacturing facilities; whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2's ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

    Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

    Investor and Media Contact:

    Carl Mauch

    Director, Investor Relations and Corporate Communications

    (617) 949-5667

    [email protected] 



    Primary Logo

    Get the next $TCRR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRR

    DatePrice TargetRatingAnalyst
    1/19/2022$28.00 → $5.00Buy → Neutral
    Goldman
    1/13/2022$25.00 → $19.00Buy
    HC Wainwright & Co.
    11/19/2021$55.00 → $26.00Overweight
    Piper Sandler
    11/10/2021$8.00 → $7.00Market Perform
    SVB Leerink
    10/21/2021$18.00 → $8.00Outperform → Mkt Perform
    SVB Leerink
    9/20/2021$40.00 → $29.00Buy
    Truist Securities
    9/20/2021$37.00 → $25.00Buy
    HC Wainwright & Co.
    9/17/2021$45.00 → $11.00Outperform → Neutral
    Wedbush
    More analyst ratings

    $TCRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tang Kevin C disposed of 4,394,800 shares (SEC Form 4)

      4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)

      2/14/24 5:25:51 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ubs Oncology Impact Fund L.P.

      4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)

      6/5/23 4:37:26 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Mpm Sunstates Fund, L.P.

      4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)

      6/5/23 4:36:51 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    SEC Filings

    See more
    • SEC Form 15-12G filed by TCR2 Therapeutics Inc.

      15-12G - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

      6/12/23 7:00:31 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TCR2 Therapeutics Inc.

      EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

      6/6/23 12:15:13 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TCR2 Therapeutics Inc.

      EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

      6/6/23 12:15:11 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies' complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the w

      5/11/23 6:30:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2's common stock to one non-executive new hire. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.77, which represents the closing market price

      5/8/23 4:05:00 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2's common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.50, which represents the closing mar

      4/3/23 4:15:00 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TCR2 Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded TCR2 Therapeutics from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

      1/19/22 7:24:24 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on TCR2 Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $19.00 from $25.00 previously

      1/13/22 6:21:23 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler resumed coverage on TCR2 Therapeutics with a new price target

      Piper Sandler resumed coverage of TCR2 Therapeutics with a rating of Overweight and set a new price target of $26.00 from $55.00 previously

      11/19/21 7:50:47 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

      SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)

      2/14/24 4:00:26 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

      SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)

      5/5/23 4:37:07 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

      SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)

      2/14/23 4:00:28 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Financials

    Live finance-specific insights

    See more
    • Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

      Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma

      3/6/23 6:00:00 AM ET
      $ADAP
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

      Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada

      3/6/23 6:00:00 AM ET
      $ADAP
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

      - Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NE

      9/28/22 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Leadership Updates

    Live Leadership Updates

    See more
    • TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

      CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. "We are excited to announce Eric Sullivan is joining the TCR2 team as Chief Financial Officer," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "Eric brings a tremendous breadth of financial,

      6/27/22 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

      CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities. "We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR2 as she has proven throughout her career an ability to work closely with multiple commercial function

      1/12/22 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors

      CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde's arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2

      8/26/21 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care